Benjamin Aaron
Family · Cookeville, TNNPI 1811454077
Payments from drug & device makers
Across 159 payments — averaging $17.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$889
- Lilly USA, LLC$302
- AstraZeneca$266
- Alkermes, Inc.$181
- Corcept Therapeutics$149
- Gilead$118
- plus $921 from 20 others
What the payments were for
- Food & beverage$2,81199%
- Education$151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 49 | $889 |
| Lilly USA, LLC | 21 | $302 |
| AstraZeneca | 15 | $266 |
| Alkermes, Inc. | 8 | $181 |
| Corcept Therapeutics | 7 | $149 |
| Gilead | 6 | $118 |
| Merck | 6 | $95 |
| Amgen | 6 | $95 |
| AbbVie | 4 | $83 |
| Phathom Pharmaceuticals, Inc. | 8 | $76 |
| Pfizer | 4 | $69 |
| Daiichi Sankyo Inc. | 3 | $64 |
| Grifols USA, LLC | 3 | $63 |
| Sanofi Pasteur Inc. | 3 | $60 |
| Otsuka America Pharmaceutical, Inc. | 2 | $40 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $36 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $34 |
| Novartis | 2 | $33 |
| GSK | 2 | $32 |
| Astellas Pharma US Inc | 1 | $26 |
| Insmed, Inc. | 1 | $23 |
| Tempus AI, Inc | 1 | $21 |
| Phadia US Inc. | 1 | $19 |
| Bayer | 1 | $18 |
| Ferring Pharmaceuticals Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
How this compares
$2,826 in reported general payments places this provider in the 80th percentile of 6,706 family providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 87 | $67,716 |
| MounjaroTirzepatide | 51 | $57,174 |
| OzempicSemaglutide | 20 | $19,928 |
| Tresiba Flextouch U-100Insulin Degludec | 32 | $19,588 |
| JardianceEmpagliflozin | 24 | $17,446 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $12,818 |
| XareltoRivaroxaban | 12 | $10,170 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $6,648 |
| Pregabalin | 40 | $6,397 |
| Repatha SureclickEvolocumab | 11 | $6,074 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $3,518 |
| Clonidine | 11 | $2,596 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 12 | $2,452 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 54 | $2,158 |
| Ventolin HfaAlbuterol Sulfate | 23 | $2,024 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $69 | $67,71687 claims |
| Lilly USA, LLCMounjaro | $302 | $57,17451 claims |
| Novo NordiskOzempic | $889 | $19,92820 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $32 | $19,46734 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,706 family providers in Tennessee.
Other family in Cookeville
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
- Lori LankfordNashville$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.